Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rastelli

Showing results (671-680 of 680) with videos related to

Pageof 68
Sort By:
You have reached the last page of results.This site can display upto 680 results.
Thoracic Cancer|February 2, 2021
Smoking status during first-line immunotherapy and chemotherapy in NSCLC patients: A case-control matched analysis from a large multicenter studyAlessio Cortellini, Andrea De Giglio, Katia Cannita, et al.
Molecules (Basel, Switzerland)|July 2, 2020
Breakthroughs in Medicinal Chemistry: New Targets and Mechanisms, New Drugs, New Hopes-7Michael Gütschow, Jean Jacques Vanden Eynde, Josef Jampilek, et al.
Sarcoidosis, Vasculitis, and Diffuse Lung Diseases : Official Journal of WASOG|November 8, 2021
Renal involvement in sarcoidosis: histological patterns and prognosis, an Italian surveyFrancesco Rastelli, Ivano Baragetti, Laura Buzzi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 1, 2023
Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with CancerAlessio Cortellini, Antonio D'Alessio, Siobhan Cleary, et al.
ESMO Open|February 26, 2022
Evaluation of COVID-19 impact on DELAYing diagnostic-therapeutic pathways of lung cancer patients in Italy (COVID-DELAY study): fewer cases and higher stages from a real-world scenarioL Cantini, G Mentrasti, G L Russo, et al.
Journal for Immunotherapy of Cancer|April 8, 2021
Differential influence of antibiotic therapy and other medications on oncological outcomes of patients with non-small cell lung cancer treated with first-line pembrolizumab versus cytotoxic chemotherapyAlessio Cortellini, Massimo Di Maio, Olga Nigro, et al.
Clinical Lung Cancer|July 19, 2020
Immune-related Adverse Events of Pembrolizumab in a Large Real-world Cohort of Patients With NSCLC With a PD-L1 Expression ≥ 50% and Their Relationship With Clinical OutcomesAlessio Cortellini, Alex Friedlaender, Giuseppe L Banna, et al.
Cancer Immunology, Immunotherapy : CII|June 1, 2020
Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of ≥ 50Alessio Cortellini, Marcello Tiseo, Giuseppe L Banna, et al.
Maturitas|November 1, 2005
Factors associated with climacteric symptoms in women around menopause attending menopause clinics in ItalyP Di Donato, N A Giulini, A Bacchi Modena, et al.
Climacteric : the Journal of the International Menopause Society|January 7, 2006
Risk factors for type 2 diabetes in women attending menopause clinics in Italy: a cross-sectional studyP Di Donato, N A Giulini, A Bacchi Modena, et al.
Pageof 68

Showing results (671-680 of 680) with videos related to

Sort By:
Pageof 68
You have reached the last page of results.This site can display upto 680 results.
Thoracic Cancer|February 2, 2021
Smoking status during first-line immunotherapy and chemotherapy in NSCLC patients: A case-control matched analysis from a large multicenter studyAlessio Cortellini, Andrea De Giglio, Katia Cannita, et al.
Molecules (Basel, Switzerland)|July 2, 2020
Breakthroughs in Medicinal Chemistry: New Targets and Mechanisms, New Drugs, New Hopes-7Michael Gütschow, Jean Jacques Vanden Eynde, Josef Jampilek, et al.
Sarcoidosis, Vasculitis, and Diffuse Lung Diseases : Official Journal of WASOG|November 8, 2021
Renal involvement in sarcoidosis: histological patterns and prognosis, an Italian surveyFrancesco Rastelli, Ivano Baragetti, Laura Buzzi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 1, 2023
Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with CancerAlessio Cortellini, Antonio D'Alessio, Siobhan Cleary, et al.
ESMO Open|February 26, 2022
Evaluation of COVID-19 impact on DELAYing diagnostic-therapeutic pathways of lung cancer patients in Italy (COVID-DELAY study): fewer cases and higher stages from a real-world scenarioL Cantini, G Mentrasti, G L Russo, et al.
Journal for Immunotherapy of Cancer|April 8, 2021
Differential influence of antibiotic therapy and other medications on oncological outcomes of patients with non-small cell lung cancer treated with first-line pembrolizumab versus cytotoxic chemotherapyAlessio Cortellini, Massimo Di Maio, Olga Nigro, et al.
Clinical Lung Cancer|July 19, 2020
Immune-related Adverse Events of Pembrolizumab in a Large Real-world Cohort of Patients With NSCLC With a PD-L1 Expression ≥ 50% and Their Relationship With Clinical OutcomesAlessio Cortellini, Alex Friedlaender, Giuseppe L Banna, et al.
Cancer Immunology, Immunotherapy : CII|June 1, 2020
Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of ≥ 50Alessio Cortellini, Marcello Tiseo, Giuseppe L Banna, et al.
Maturitas|November 1, 2005
Factors associated with climacteric symptoms in women around menopause attending menopause clinics in ItalyP Di Donato, N A Giulini, A Bacchi Modena, et al.
Climacteric : the Journal of the International Menopause Society|January 7, 2006
Risk factors for type 2 diabetes in women attending menopause clinics in Italy: a cross-sectional studyP Di Donato, N A Giulini, A Bacchi Modena, et al.
Pageof 68